Schliack M, Löser R, Seibel K, Rattel B, Lang G
Klinge Pharma GmbH, München, F.R.G.
Artery. 1990;18(1):1-15.
We investigated the hypolipidemic property of lifibrol in male and female minipigs in a long term trial over a treatment period of 6 months. Oral dosages between 12.5 mg/kg BW and 100 mg/kg BW lifibrol resulted in a strong reduction of serum cholesterol after only two weeks of treatment. The hypocholesterolemic effect was not counterbalanced and reached -76% at the end of the trial in the male pigs and -70% in the female pigs (100 mg/kg BW lifibrol). The reduction of serum cholesterol was mainly brought about by the reduction of LDL-cholesterol. Serum triglycerides seemed to be less influenced by lifibrol than serum cholesterol. The application of lifibrol had no significant influence on the weight gain of the pigs and did not alter the serum levels of AST and ALT. Lifibrol was well tolerated and the animals showed no symptoms of incompatibility.
我们在一项为期6个月的长期试验中,研究了利非布罗对雄性和雌性小型猪的降血脂特性。口服剂量在12.5毫克/千克体重至100毫克/千克体重之间的利非布罗,仅在治疗两周后就使血清胆固醇大幅降低。在试验结束时,雄性猪的降胆固醇作用未被抵消,达到了-76%,雌性猪(100毫克/千克体重利非布罗)达到了-70%。血清胆固醇的降低主要是由于低密度脂蛋白胆固醇的降低。利非布罗对血清甘油三酯的影响似乎比对血清胆固醇的影响小。利非布罗的应用对猪的体重增加没有显著影响,也没有改变血清AST和ALT水平。利非布罗耐受性良好,动物未出现不相容症状。